propranolol treatment

Phase 3Small molecule

UUniversity Hospital, Bordeaux

propranolol treatment is one of 20 small molecule programs targeting Capillary Hemangioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Capillary HemangiomaActive, not recruiting

Hereditary Hemorrhagic TelangiectasiaActive, not recruiting

Capillary HemangiomaPhase 2/Phase 3

Active, not recruiting

Hereditary Hemorrhagic TelangiectasiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Hereditary Hemorrhagic Telangiectasia

#DrugCompanyPhaseTrials

Inderal

WWyeth-Lederle Vaccines

Bactroban

Avastin

7 4

Votrient

Novartis

Phase 2

2 5

Nolvadex

AstraZeneca

Phase 2

1 6

Thalomid

Bristol-Myers Squibb

Phase 2

1 7

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

2 8

Cyklokapron

AAmring

Phase 2

1 9

Sandostatin

Sun Pharma

Phase 2

1 10

Doryx

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Capillary Hemangioma1 trial

Propranolol in Capillary Hemangiomas

Terminated·UUniversity Hospital, Bordeaux·Phase 2/3·NCT00744185·14 enrolled

Hereditary Hemorrhagic Telangiectasia1 trial

Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients

Terminated·UUniversity Hospital, Bordeaux·Phase 3·NCT04113187·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for propranolol treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — propranolol treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for propranolol treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bordeaux company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Bordeaux

propranolol treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Capillary Hemangioma1 trial

Hereditary Hemorrhagic Telangiectasia1 trial

References

Drug Info

Quick Facts

Related News